TMO Thermo Fisher Scientific Loading...

From RVTY earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
13:00
Feb 02 ◎
Prahlad Singh CEO, Revvity, Inc. RVTY Q4 FY25 call
Life sciences instruments saw a strong double-digit sequential revenue increase from Q3 to Q4 2025 and were roughly flat year-over-year, marking a meaningful improvement versus the significant declines seen over the prior three years. — OES demand is showing signs of stabilization and potential recovery, which is a leading indicator for the broader life sciences tools sector.
TMO
MED

About TMO Analyst Coverage

Buzzberg tracks TMO (Thermo Fisher Scientific) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 1 total trade idea tracked. Latest voices: Prahlad Singh.